Literature DB >> 23278424

Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF.

Caroline Gouarné1, Marc Giraudon-Paoli, Mathieu Seimandi, Clotilde Biscarrat, Gwenaëlle Tardif, Rebecca M Pruss, Thierry Bordet.   

Abstract

BACKGROUND AND
PURPOSE: Olesoxime is a small cholesterol-oxime promoting rat embryonic motor neurons survival in the absence of trophic factors. Because olesoxime can substitute for neurotrophic factors in many situations, and to gain further understanding of its mechanism of action, we wondered if it could prevent neuronal death induced by camptothecin (CPT) and compared its effects with those of brain-derived neurotrophic factor (BDNF). EXPERIMENTAL APPROACH: E17 rat embryonic cortical neurons were treated with olesoxime, BDNF or vehicle and intoxicated with CPT. Caspase-dependent and caspase-independent death pathways along with pro-survival pathways activation were explored. KEY
RESULTS: As previously reported for BDNF, olesoxime dose-dependently delayed CPT-induced cell death. Both compounds acted downstream of p53 activation preventing cytochrome c release and caspases activation. When caspase activation was blocked, both olesoxime and BDNF provided additional neuroprotective effect, potentially through the prevention of apoptosis-inducing factor release from mitochondria. While BDNF activates both the PI3K/Akt and the ERK pathway, olesoxime induced only a late activation of the ERK pathways, which did not seem to play a major role in its neuroprotection against CPT. Rather, our results favour preserved mitochondrial membrane integrity by olesoxime. CONCLUSIONS AND IMPLICATIONS: Albeit different, olesoxime and BDNF mechanisms for neuroprotection converge to preserve mitochondrial function. These findings emphasize the importance of targeting the mitochondria in the process of neurodegeneration. Importantly olesoxime, by mimicking neurotrophin pro-survival activities without impacting PI3K/Akt and ERK signalling, may have greater therapeutic potential in many diseases where neurotrophins were considered as a therapeutic solution.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23278424      PMCID: PMC3623066          DOI: 10.1111/bph.12094

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  65 in total

1.  Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways.

Authors:  R D Almeida; B J Manadas; C V Melo; J R Gomes; C S Mendes; M M Grãos; R F Carvalho; A P Carvalho; C B Duarte
Journal:  Cell Death Differ       Date:  2005-10       Impact factor: 15.828

2.  Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum.

Authors:  Esther Pérez-Navarro; Núria Gavaldà; Elena Gratacòs; Jordi Alberch
Journal:  J Neurochem       Date:  2005-02       Impact factor: 5.372

3.  Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase.

Authors:  M Hetman; K Kanning; J E Cavanaugh; Z Xia
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

4.  The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin.

Authors:  Yi Zhang; Dianbo Qu; Erick J Morris; Michael J O'Hare; Steven M Callaghan; Ruth S Slack; Herbert M Geller; David S Park
Journal:  J Neurosci       Date:  2006-08-23       Impact factor: 6.167

5.  Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons.

Authors:  L Stefanis; D S Park; W J Friedman; L A Greene
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

6.  Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms.

Authors:  Eric C C Cheung; Lysanne Melanson-Drapeau; Sean P Cregan; Jacqueline L Vanderluit; Kerry L Ferguson; William C McIntosh; David S Park; Steffany A L Bennett; Ruth S Slack
Journal:  J Neurosci       Date:  2005-02-09       Impact factor: 6.167

7.  Trk receptor alterations in Alzheimer's disease.

Authors:  B Connor; D Young; P Lawlor; W Gai; H Waldvogel; R L Faull; M Dragunow
Journal:  Brain Res Mol Brain Res       Date:  1996-11

Review 8.  Gene therapy targeting to tumor endothelium.

Authors:  M Bazan-Peregrino; L W Seymour; A L Harris
Journal:  Cancer Gene Ther       Date:  2006-11-10       Impact factor: 5.987

9.  N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway.

Authors:  Daming Zhu; Xuan Wu; Kenneth I Strauss; Robert H Lipsky; Zehra Qureshi; Artin Terhakopian; Antonello Novelli; Krishna Banaudha; Ann M Marini
Journal:  J Neurosci Res       Date:  2005-04-01       Impact factor: 4.164

10.  Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Authors:  Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

View more
  8 in total

Review 1.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

2.  Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Authors:  Franziska Richter; Fuying Gao; Vera Medvedeva; Patrick Lee; Nicholas Bove; Sheila M Fleming; Magali Michaud; Vincent Lemesre; Stefano Patassini; Krystal De La Rosa; Caitlin K Mulligan; Pedrom C Sioshansi; Chunni Zhu; Giovanni Coppola; Thierry Bordet; Rebecca M Pruss; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2014-05-18       Impact factor: 5.996

3.  Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells.

Authors:  C Gouarné; J Tracz; M Giraudon Paoli; V Deluca; M Seimandi; G Tardif; M Xilouri; L Stefanis; T Bordet; R M Pruss
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 4.  VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease.

Authors:  William M Rosencrans; Megha Rajendran; Sergey M Bezrukov; Tatiana K Rostovtseva
Journal:  Cell Calcium       Date:  2021-01-23       Impact factor: 6.817

5.  Exploring lipid-dependent conformations of membrane-bound α-synuclein with the VDAC nanopore.

Authors:  David P Hoogerheide; Tatiana K Rostovtseva; Sergey M Bezrukov
Journal:  Biochim Biophys Acta Biomembr       Date:  2021-05-07       Impact factor: 4.019

6.  The calpain-suppressing effects of olesoxime in Huntington's disease.

Authors:  Jonasz J Weber; Midea M Ortiz Rios; Olaf Riess; Laura E Clemens; Huu P Nguyen
Journal:  Rare Dis       Date:  2016-04-06

Review 7.  Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy.

Authors:  Hannah K Shorrock; Thomas H Gillingwater; Ewout J N Groen
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

8.  Adverse effects of Δ9-tetrahydrocannabinol on neuronal bioenergetics during postnatal development.

Authors:  Johannes Beiersdorf; Zsofia Hevesi; Daniela Calvigioni; Jakob Pyszkowski; Roman Romanov; Edit Szodorai; Gert Lubec; Sally Shirran; Catherine H Botting; Siegfried Kasper; Geoffrey W Guy; Roy Gray; Vincenzo Di Marzo; Tibor Harkany; Erik Keimpema
Journal:  JCI Insight       Date:  2020-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.